Global Idiopathic Gastroparesis Drugs Market Anticipated to Reach US$ 1,699.3 Million by 2030

According to a recent market study published by Growth Market Reports, titled, “Idiopathic Gastroparesis Drugs Market by Drug Type, by Route of Administration, by Distribution Channel, and by Region: Size, Share, Trends and Opportunity Analysis, 2015-2030”, the market was valued at US$ 1,192.7 Million in 2021 and is expected to expand at a growth rate of 4.1% by 2030.

Gastroparesis is a chronic disorder where the movement of stomach muscles slows or stops, leading to non-emptying of the stomach. Gastroparesis occurs due to diabetes and post-surgical complications. The reason of gastroparesis is not known in some cases, which is called idiopathic gastroparesis. The treatment of idiopathic gastroparesis includes surgical and drug-based regimes. Along with a healthy diet, doctors recommend medications such as antiemetic drugs and prokinetic drugs for treating idiopathic gastroparesis.

The idiopathic gastroparesis drugs market has been fragmented based on drug type, route of administration, and distribution channel. By drug type, the global idiopathic gastroparesis drugs market is categorized as antiemetic drugs, prokinetic drugs, and others. In terms of route of administration, the market is categorized as oral, intravenous, nasal, and transdermal. By distribution channel, the market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. Considering regions, the market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa.

Get Sample Report @ https://growthmarketreports.com/request-sample/5065

The Coronavirus disease 2019 (COVID-19) pandemic highlighted economic disparities, global interdependence, and governance challenges. However, the COVID-19 outbreak has slightly negative impact on the consumption rate of gastroparesis drugs, due to the lack of a defined line of treatment during the pandemic. The pandemic disrupted various businesses and supply chains. The production chain for these therapeutic agents was somewhat reduced. Gastroparesis drugs were consumed through over the counter (OTC) and for the treatment of side-effects, such as vomiting and nausea.

As per Growth Market Reports industry analyst, Ruchika Sharma, “The expanding healthcare and R&D activities are expected to contribute to the growth of the global idiopathic gastroparesis drugs market. Advances in research and development, treatment for idiopathic gastroparesis, and the rising prevalence of non-emptying of stomach due to damaged stomach muscles are contributing to the expansion of the idiopathic gastroparesis drugs market. Demand for idiopathic gastroparesis drugs is projected to grow in the coming years, due to rising cases of idiopathic gastroparesis caused by reasons other than diabetic and post-surgical gastroparesis.”
A supply chain is a network between manufacturers and suppliers to produce and distribute a specific product to the final buyers. This network includes different people, regulatory bodies, entities, information, and resources. Entities in the supply chain include raw material suppliers, manufacturers, logistics, warehouses, pharmacies, finance, distributors, and customers. Supply chain management is an essential part of any business. If the supply chain of idiopathic gastroparesis drugs is hampered, the patients suffering from chronic ailments are not treated on time, resulting in the gastroenterology conditions.

Key Takeaways from the Study:

• Players in the global idiopathic gastroparesis drugs market include EVOKE PHARMA, Cadila Pharmaceuticals, Janssen-Cilag Pty Limited, Abbott, ADVANZ PHARMA, iNova Pharmaceuticals, ANI Pharmaceuticals, Inc., AstraZeneca, Intas Pharmaceuticals Ltd., Cipla Inc. held a major market share of the idiopathic gastroparesis drugs market in 2021.
• Rising approval of medications with different routes of administration and increasing prevalence of gastroparesis cases are contributing to the growth of the global idiopathic gastroparesis drugs market.
• In terms of drug type, the global idiopathic gastroparesis drugs market is categorized as antiemetic drugs, prokinetic drugs, and others. The antiemetic drugs segment is projected to account for a substantial share of the idiopathic gastroparesis drugs market during the forecast period. Prokinetic drugs are crucial for the treatment of idiopathic gastroparesis. Various examples of prokinetic drugs are erythromycin, domperidone, and cisapride, among others.
• Based on route of administration, the global idiopathic gastroparesis drugs market is categorized as oral, intravenous, nasal, and transdermal. The oral segment is projected to hold a significant share of the market during the forecast period, as oral pills are easy to consume by patients for the treatment of gastroparesis complications. Intravenous is a painful way of administering drugs to patients.
• In terms of regions, the global idiopathic gastroparesis drugs market is divided into North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. North America is projected to account for a significant share of the idiopathic gastroparesis drugs market during the forecast period, owing to the increasing facilities for treatment and well-established healthcare system in the region. Europe holds a large share of the market, due to rising R&D activities in the region.

Report Scope:

Target Audience:

• Supply-side: Manufacturers and distributors
• Demand Side: Healthcare industry and pharmaceutical industry
• Regulatory Side: Concerned government authorities and other approved regulatory bodies
• Associations and Industry Bodies: Food and Drug Administration (FDA) and World Health Organization (WHO)